Cargando…

Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer

OBJECTIVES: The aim was to explore the prognostic significance of IL-6 and markers of systemic inflammatory response (SIR), in particular C-reactive protein (CRP), in metastatic colorectal cancer (mCRC) patients, in the total study population and according to RAS and BRAF mutation status. RESULTS: H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thomsen, Maria, Kersten, Christian, Sorbye, Halfdan, Skovlund, Eva, Glimelius, Bengt, Pfeiffer, Per, Johansen, Julia S., Kure, Elin H., Ikdahl, Tone, Tveit, Kjell Magne, Christoffersen, Thoralf, Guren, Tormod Kyrre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342719/ https://www.ncbi.nlm.nih.gov/pubmed/27738330 http://dx.doi.org/10.18632/oncotarget.12601

Ejemplares similares

Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome
por: Thomsen, Maria, et al.
Publicado: (2018)

Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study
por: Guren, Tormod Kyrre, et al.
Publicado: (2017)

Let-7 miRNA-binding site polymorphism in the KRAS 3(′)UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/− cetuximab
por: Kjersem, Janne B, et al.
Publicado: (2012)

Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab: RESULTS from the NORDIC VII Study
por: Tarpgaard, Line S., et al.
Publicado: (2014)

Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer
por: Mezheyeuski, Artur, et al.
Publicado: (2016)

TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: A potential novel approach to the treatment of metastatic colorectal cancer
por: Tarpgaard, Line S., et al.
Publicado: (2016)

FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab
por: Kjersem, Janne B, et al.
Publicado: (2014)

Survival Trends of Right- and Left-Sided Colon Cancer across Four Decades: A Norwegian Population-Based Study
por: Hamfjord, Julian, et al.
Publicado: (2022)

Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer
por: Mezheyeuski, Artur, et al.
Publicado: (2017)

Health-Related Quality of Life in Colorectal Cancer Patients Treated With Liver Transplantation Compared to Chemotherapy
por: Smedman, Tor Magnus, et al.
Publicado: (2022)

Differential Expression of miRNAs in Colorectal Cancer: Comparison of Paired Tumor Tissue and Adjacent Normal Mucosa Using High-Throughput Sequencing
por: Hamfjord, Julian, et al.
Publicado: (2012)

Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9
por: Winther, Stine Braendegaard, et al.
Publicado: (2017)

High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer
por: Siesing, Christina, et al.
Publicado: (2017)

CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup
por: Aasebø, Kristine, et al.
Publicado: (2020)

Consequences of a high incidence of microsatellite instability and BRAF‐mutated tumors: A population‐based cohort of metastatic colorectal cancer patients
por: Aasebø, Kristine Ø., et al.
Publicado: (2019)

High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort
por: Sorbye, Halfdan, et al.
Publicado: (2015)

Mechanisms involved in PGE(2)-induced transactivation of the epidermal growth factor receptor in MH(1)C(1) hepatocarcinoma cells
por: Tveteraas, Ingun Heiene, et al.
Publicado: (2012)

The level of claudin-7 is reduced as an early event in colorectal carcinogenesis
por: Bornholdt, Jette, et al.
Publicado: (2011)

Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma
por: Lorentzen, Anders, et al.
Publicado: (2007)

The Prognostic Value of Pre-Treatment Circulating Biomarkers of Systemic Inflammation (CRP, dNLR, YKL-40, and IL-6) in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy—The Randomized NORDIC9-Study
por: Liposits, Gabor, et al.
Publicado: (2022)

Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer
por: Meltzer, Sebastian, et al.
Publicado: (2022)

Duodenogastric Reflux Increases the Penetration of N‐(3)H‐Methyl‐N‐nitro‐N‐nitrosoguanidine into the Antral Mucosa of Rats: A Possible Role for Mucosal Erosions and Increased Cell Proliferation in Gastric Carcinogenesis
por: Øvrebø, Kjell K., et al.
Publicado: (2002)

Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy—The Randomized NORDIC9-Study
por: Liposits, Gabor, et al.
Publicado: (2021)

Collagen mRNA levels changes during colorectal cancer carcinogenesis
por: Skovbjerg, Hanne, et al.
Publicado: (2009)

Meat, vegetables and genetic polymorphisms and the risk of colorectal carcinomas and adenomas
por: Skjelbred, Camilla F, et al.
Publicado: (2007)

Lower treatment intensity and poorer survival in metastatic colorectal cancer patients who live alone
por: Cavalli-Björkman, N, et al.
Publicado: (2012)

KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer
por: Osterlund, Emerik, et al.
Publicado: (2022)

Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial
por: Aamdal, Elin, et al.
Publicado: (2021)

Evidence for the involvement of G(i2) in activation of extracellular signal-regulated kinases in hepatocytes
por: Melien, Øyvind, et al.
Publicado: (2001)

Expression of prostasin and its inhibitors during colorectal cancer carcinogenesis
por: Selzer-Plon, Joanna, et al.
Publicado: (2009)

Survival According to Primary Tumor Location, Stage, and Treatment Patterns in Locoregional Gastroenteropancreatic High-grade Neuroendocrine Carcinomas
por: Dasari, Arvind, et al.
Publicado: (2022)

Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases
por: Løes, Inger Marie, et al.
Publicado: (2016)

The internal structure of foster-parent completed SDQ for school-aged children
por: Lehmann, Stine, et al.
Publicado: (2017)

Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer
por: Brunsvig, Paal F., et al.
Publicado: (2020)

Patient reported symptoms, coping and quality of life during somatostatin analogue treatment for metastatic small- intestinal neuroendocrine tumours
por: Sorbye, Halfdan, et al.
Publicado: (2020)

Functional heterogeneity in tumor-derived human pancreatic stellate cells: Differential expression of HGF and implications for mitogenic signaling and migration in pancreatic cancer cells
por: Tjomsland, Vegard, et al.
Publicado: (2017)

Multidisciplinary treatment of patients with rectal cancer: Development during the past decades and plans for the future
por: Glimelius, Bengt
Publicado: (2012)

Optimal Time Intervals between Pre-Operative Radiotherapy or Chemoradiotherapy and Surgery in Rectal Cancer?
por: Glimelius, Bengt
Publicado: (2014)

On a prolonged interval between rectal cancer (chemo)radiotherapy and surgery
por: Glimelius, Bengt
Publicado: (2017)

Calmangafodipir for Prevention of Oxaliplatin-Induced Peripheral Neuropathy: Two Placebo-Controlled, Randomized Phase 3 Studies (POLAR-A/POLAR-M)
por: Pfeiffer, Per, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rq1gfc4m7i25derkntjoc0ve1k